Results 131 to 140 of about 12,970 (183)

Editorial: Community series: systemic vasculitis: advances in pathogenesis and therapies, volume II. [PDF]

Front Immunol
De Souza AWS, Ooi JD, Deng J, Croci S, Gan PY, Brown KL.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Management of Hyperhomocysteinemia

Metabolic Syndrome and Related Disorders, 2003
Hyperhomocysteinemia is an established risk factor for cardiovascular disease. The modification of traditional cardiovascular risk factors has resulted in better morbidity and mortality outcomes, so the treatment of hyperhomocysteinemia is explored for a similar benefit.
Emily, Chan, Vivian A, Fonseca
openaire   +2 more sources

Hyperhomocysteinemia and thrombosis

Hematology/Oncology Clinics of North America, 2003
Homocysteine remains an enigmatic marker for vascular disease. Studies have shown hyperhomocysteinemia is a risk factor for VTE, cerebrovascular disease, and coronary artery disease. This relationship, however, has not been consistently corroborated by studies of patients with genetic polymorphisms that alter homocysteine metabolism.
Ray, Lee, Eugene P, Frenkel
openaire   +2 more sources

Hyperhomocysteinemia and Thrombosis

Seminars in Thrombosis and Hemostasis, 1999
Homocysteine has been identified as an independent risk factor for atherosclerotic and thrombotic disease. Both arterial (cerebrovascular, carotid, coronary, and peripheral arterial) and veno-occlusive disease, jointly termed vascular occlusive disease (VOD) in this review, have been associated with hyperhomocysteinemia.
S C, Guba, V, Fonseca, L M, Fink
openaire   +2 more sources

Hyperhomocysteinemia in dementia

Journal of Neural Transmission, 2000
Hyperhomocysteinemia is a strong risk factor for atherosclerotic vascular disease, and elevated serum homocysteine is correlated with vitamin B deficiency. In this pilot study, significantly elevated homocysteine levels were found in patients with Alzheimer's disease as well as in patients with vascular dementia, probably indicating similar ...
F, Leblhuber, J, Walli, E, Artner-Dworzak, K, Vrecko, B, Widner, G, Reibnegger, D, Fuchs   +6 more
openaire   +2 more sources

Investigation of hyperhomocysteinemia

Annales de biologie clinique, 2013
Hyperhomocysteinemia has been described as a risk factor for venous and arterial thromboembolic diseases but may be also involved in neurodegenerative and neuropsychiatric disorders. Considering some arguments for homocysteine (Hcy) toxicity, a systematic investigation tool of hyperhomocysteinemia is needed.
Charlotte, Veyrat-Durebex, Hélène, Blasco, Julie, Crinier, Caroline, Vayne, Patrick, Emond, François, Labarthe, Christian R, Andres, François, Maillot   +7 more
openaire   +2 more sources

Hyperhomocysteinemia and Restenosis

European Journal of Cardiovascular Prevention & Rehabilitation, 2001
This study was undertaken to assess the effect of plasma homocysteine level on angiographic restenosis 6 months after coronary angioplasty.The plasma homocysteine level was measured in 100 consecutive patients at the time of coronary angioplasty, 56 patients who attended a 6-month follow-up angiogram being enrolled to the study; the 44 patients without
S D, Kumbasar, I, Dinçer, F, Ertas, S, Gülec, C, Erol, O, Akyürek, M, Kiliçkap, D, Oral, E, Sipahi, Y, Laleli   +9 more
openaire   +2 more sources

Hyperhomocysteinemia and cardiovascular diseases

Annales de Biologie Clinique, 2022
Homocysteine (Hcy) is a sulfhydryl-containing amino acid, which is not acquired through the diet, but rather synthesized as an intermediate metabolite in the methionine cycle. Hcy is present in plasma, with normal levels between 5 and 15 μmol/L, a slightly elevated level between 15 to 30 μmol/L, moderate from 30 to 100 μmol/L and a value > 100 μmol/L ...
Guieu, Régis, Ruf, Jean, Mottola, Giovanna   +2 more
openaire   +4 more sources

Hyperhomocysteinemia and thrombophilia

Clinical Chemistry and Laboratory Medicine, 2010
It is now widely accepted that hyperhomocysteinemia (HHC) is a risk factor for thrombophilia. HHC is the result of either impaired enzyme function or a deficiency of vitamin B (folate, B₆, B₁₂), or both, and can be treated with vitamin supplements.
openaire   +2 more sources